pH-responsive antibodies for therapeutic applications
Open Access
- 22 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 28 (1), 1-14
- https://doi.org/10.1186/s12929-021-00709-7
Abstract
Therapeutic antibodies are instrumental in improving the treatment outcome for certain disease conditions. However, to enhance their efficacy and specificity, many efforts are continuously made. One of the approaches that are increasingly explored in this field are pH-responsive antibodies capable of binding target antigens in a pH-dependent manner. We reviewed suitability and examples of these antibodies that are functionally modulated by the tumor microenvironment. Provided in this review is an update about antigens targeted by pH-responsive, sweeping, and recycling antibodies. Applicability of the pH-responsive antibodies in the engineering of chimeric antigen receptor T-cells (CAR-T) and in improving drug delivery to the brain by the enhanced crossing of the blood–brain barrier is also discussed. The pH-responsive antibodies possess strong treatment potential. They emerge as next-generation programmable engineered biologic drugs that are active only within the targeted biological space. Thus, they are valuable in targeting acidified tumor microenvironment because of improved spatial persistence and reduced on-target off-tumor toxicities. We predict that the programmable pH-dependent antibodies become powerful tools in therapies of cancer.Keywords
This publication has 122 references indexed in Scilit:
- Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In VivoPLOS ONE, 2013
- Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9*Online Journal of Public Health Informatics, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- A combinatorial histidine scanning library approach to engineer highly pH‐dependent protein switchesProtein Science, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin ReceptorMolecular Pharmaceutics, 2009
- The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapyBritish Journal of Cancer, 2009
- Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouseBiotechnology & Bioengineering, 2008
- CNS immune privilege: hiding in plain sightImmunological Reviews, 2006
- The Hallmarks of CancerCell, 2000